The key in clinical translation of GLUT inhibitor treatments involves the following: (i) the identification of a therapeutic window exploiting the increased dependence of cancer cells on glucose as compared with normal tissues and (ii) the development of specific inhibitors that can target alternative transporters with less prominent physiological functions than GLUT1, such as class III GLUTs. This evidence concerns the gene SLC2A1 and cancer.